Erciyes University Hematology Hospital

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia	Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy	Recruiting	Phase 3	2026-04-08		NCT07233213

Clinical trials